We are testing a new cell infusion treatment for patients with relapsed or refractory aggressive B-cell lymphoma. This study aims to see how well ARI0003 cells work in helping these patients.
Health conditions and diseases that the clinical trial is designed to study and treat.
Aggressive B-cell lymphoma is a type of cancer that originates from B-lymphocytes, characterized by rapid growth and the potential to spread quickly. It includes various subtypes like Burkitt's lymphoma and high-grade B-cell lymphoma, often requiring intensive treatment.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.